LB Pharmaceuticals Inc
LBRX
$47.78
$3.517.92%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 49.52% | 13.91% | -1.57% | -- | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 176.61% | -16.69% | -53.82% | -- | -- |
| Operating Income | -176.61% | 16.69% | 53.82% | -- | -- |
| Income Before Tax | -189.03% | 25.04% | 59.71% | -- | -- |
| Income Tax Expenses | 0.00% | 0.00% | 0.00% | -- | -- |
| Earnings from Continuing Operations | -189.02% | 25.04% | 59.71% | -- | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -189.02% | 25.04% | 59.71% | -- | -- |
| EBIT | -176.61% | 16.69% | 53.82% | -- | -- |
| EBITDA | -177.58% | 17.03% | 54.25% | -- | -- |
| EPS Basic | 96.11% | 83.51% | 80.30% | -- | -- |
| Normalized Basic EPS | 96.29% | 70.82% | 70.89% | -- | -- |
| EPS Diluted | 96.11% | 83.51% | 80.30% | -- | -- |
| Normalized Diluted EPS | 96.29% | 70.82% | 70.89% | -- | -- |
| Average Basic Shares Outstanding | 6,641.85% | 5,443.26% | 3,187.90% | -- | -- |
| Average Diluted Shares Outstanding | 6,641.85% | 4,400.38% | 2,513.85% | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |